IQVIA (NYSE:IQV) Hits New 12-Month High – Here’s Why

IQVIA Holdings Inc. (NYSE:IQV) hit a new 52-week high during trading on Monday . The company traded as high as $234.50 and last traded at $234.5510, with a volume of 1012163 shares trading hands. The stock had previously closed at $225.37.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. JPMorgan Chase & Co. upped their price target on shares of IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Citigroup boosted their target price on IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a research note on Wednesday, October 29th. Cowen cut IQVIA from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, December 20th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $243.19.

IQVIA Trading Up 4.0%

The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The stock’s fifty day moving average price is $222.34 and its 200 day moving average price is $198.36. The stock has a market cap of $39.93 billion, a P/E ratio of 32.17, a PEG ratio of 2.29 and a beta of 1.36.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the business earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is owned by insiders.

Institutional Investors Weigh In On IQVIA

A number of large investors have recently added to or reduced their stakes in IQV. Brighton Jones LLC lifted its stake in IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its position in shares of IQVIA by 85.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 72,201 shares of the medical research company’s stock worth $12,729,000 after buying an additional 33,341 shares in the last quarter. Advisors Asset Management Inc. grew its holdings in IQVIA by 25.3% during the 1st quarter. Advisors Asset Management Inc. now owns 5,826 shares of the medical research company’s stock valued at $1,027,000 after buying an additional 1,176 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in IQVIA by 0.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,282 shares of the medical research company’s stock worth $8,865,000 after acquiring an additional 281 shares during the last quarter. Finally, NewEdge Advisors LLC raised its holdings in shares of IQVIA by 13.9% during the 1st quarter. NewEdge Advisors LLC now owns 21,576 shares of the medical research company’s stock worth $3,804,000 after acquiring an additional 2,626 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.